Karolinska Development AB (publ) – Interim Report

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Karolinska Development AB (publ) – Interim Report January – September 2014

Bruno Lucidi, CEO, comments: “My appointment as CEO of Karolinska Development coincides with the announcement of a new strategy for the future investments in our portfolio. I am convinced that these strategic measures will be a good foundation for our continued efforts to realize value in the portfolio.

Our portfolio companies have been selected into a Strategic and an Opportunistic Portfolio that we further specify in this report. We will focus our financial and managerial efforts in the Strategic Portfolio and develop those towards important near-to mid-term value inflection point within specialized care areas and orphan diseases such as Dilaforette’s program in sickle-cell disease or OssDsign’s advanced implant technology. At the same time we will utilize a more differentiated investment strategy depending on the properties of the programs within the portfolio. In order to maximize value and future returns, the investment horizon for each asset will for example vary depending on the optimal exit strategy within the specific therapeutic fields.    

We were pleased to announce Forendo Pharma’s licensing agreement granting Apricus Bioscience US development and commercialization rights for fispemifene after the reporting period. The agreement does not only signify the Forendo team’s expert abilities in developing drug candidates that targets organ specific hormone mechanisms, but also exemplifies the value potential in our portfolio of  carefully selected innovations based on outstanding science.  According to the deal terms, Forendo is entitled to a total of USD 310 million in milestone and upfront payments, common shares in Apricus and tiered double-digit royalties on US net sales. The fispemifene development program will focus on hypogonadism, a condition that results in low testosterone levels in men, where two Phase II studies has shown therapeutic potential. In addition, Apricus will expand the development into other urological conditions where the fispemifene mode of action is believed to able to ameliorate symptoms.

It is important to emphasize that the Opportunistic Portfolio also hold a considerable value potential. During the third quarter, Umecrine Mood presented final data from the company’s exploratory Phase I/II study in patients with premenstrual dysphoric disorder (PMDD). While the study’s primary endpoint was not met, as we announced during the summer, post-hoc analyses correcting for some important issues identified in the study, shows significant reductions in symptoms compared to placebo. Should these data be confirmed in new studies, UC1010 could make a profound difference to the millions of women who suffer from PMDD. Based on these data, Umecrine Mood are now in the process of finding a partner to continue the clinical development of UC1010.

In October, Athera Biotechnologies passed an important milestone in the development of PC-mAb for the treatment of cardiovascular disease when the first patients were dosed in a Phase I study. In addition, Clanotech received orphan drug designation in the EU for the development of the company’s lead candidate within glaucoma surgery. Furthermore, OssDsign received 510(k) clearance by the US FDA for the burr hole plug Cranioplug.

In our continuous effort to evaluate the portfolio, the fair value of Biosergen has written down as the company has not been able to secure external financing to the systemic fungal infection in preclinical development.

I am looking forward to leading Karolinska Development in this decisive period for the company. With a new strategy in place, we will move forward determinately to unlock the value in our portfolio. Our belief that investing in outstanding life science innovations will shape future treatments for patients that today are not offered adequate treatment options. The management in our portfolio companies are key to the success of our ambitions. The new strategy will also take into consideration the specific needs within the portfolio of accountable and experienced leadership.”

Summary of significant events during the third quarter 2014

  • Klaus Wilgenbus appointed as acting CEO
  • Umecrine Mood announced final results from an exploratory Phase I/II study with UC1010 in premenstrual dysphoric disorder
  • Bruno Lucidi appointed as CEO in Karolinska Development oncology companies

Summary of significant events after the third quarter 2014

  • Bruno Lucidi appointed as new CEO of  Karolinska Development
  • Forendo Pharma announced the US licensing of fispemifene to Apricus Biosciences
  • Clanotech received orphan drug designation in the EU
  • OssDsign’s Cranioplug received marketing approval in the US
  • Athera initiated Phase I study with cardiovascular antibody PC-mAb
  • Karolinska Development presented an updated strategy
  • Danske Bank appointed as financial advisor

Financial summary

SEKm 2014 Jul-Sep 2013 Jul-Sep (restated) 2014 Jan-Sep 2013 Jan-Sep (restated) 2013 (restated)
Condensed Income Statement          
Change in fair value of portfolio companies -107.7 -80.6 -291.1 -16.6 -140.0
Net profit/loss -128.1 -91.6 -336.0 -58.1 -157.3
Condensed Balance sheet          
Cash, cash equivalents and short-term investments     112.3 232.1 200.7
Share information          
Earnings per share, weighted average, before and after dilution (SEK) -2.65 -1.90 -6.96 -1.20 -3.25
Net asset value per share (SEK)     33.9 42.6 40.7
Equity per share (SEK)     33.6 42.6 40.5
Share price, last trading day in the reporting period (SEK)     13.0 31.0 30.9
Portfolio information          
Portfolio companies´net cash¹)     -2.8 186.9 111.6
Investments in portfolio companies 7.2 2.7 56.5 176.9 266.2
Of which investments not affecting cash flow 0.0 0.0 6.7 3.8 68.1
Fair value of portfolio holdings     1,494.0 1,767.8 1,729.5

 ¹)  Portfolio companies' net cash is comprised of sum of cash, cash equivalents and short-term investments less external loans in portfolio companies regardless of Karolinska Development's ownership interest (cash, cash equivalents and short-term investments amounting to SEK 92.7m less external loans amounting to SEK -95.5m)

 

For further information, please contact: Bruno Lucidi, CEO, Karolinska Development AB Phone: +46 72 245 9892, e-mail: bruno.lucidi@karolinskadevelopment.com

Christian Tange, CFO, Karolinska Development AB Phone: +46 (0)73 712 14 30, e-mail: christian.tange@karolinskadevelopment.com

TO THE EDITORS

About Karolinska Development AB Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into differentiated products that can be partnered. The business model is to: SELECT the most commercially attractive medical innovations that can potentially satisfy unmet medical needs; DEVELOP innovations to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products. An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading universities, delivers a continuous flow of innovations. For more information, please visit www.karolinskadevelopment.com.

Karolinska Development is listed on NASDAQ OMX. Karolinska Development may be required to disclose the information provided herein pursuant to the Securities Markets Act.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Unilumin's APEC 2026 Showcase Is a Useful Field Test

Updated Category News Views 41

Few sales pitches get stress-tested by a thousand journalists, a major airport, and a leaders' summit all at once. That is the useful part of Unilumin's role as an official sponsor of APEC 2026 in Shenzhen. The company says its LED systems were installed across summit venues, the media center, transportation hubs, and city landmarks as the 33rd APEC Economic Leaders'...

Continue Reading
Paratus on the Move: Seagems JV Under the Microscope

Updated Category News Views 131

What's Cooking with Paratus Energy? Paratus Energy Services Ltd. (ticker: PLSV) just threw us a curveball, announcing a strategic review of its participation in the Seagems joint venture. Now, before you get too jazzed about ticker talk—hold your horses. No one's making any promises about transactions just yet. The decision's still hanging in the balance, even as they...

Continue Reading
MAXHUB's Canon Office Test Puts Hybrid Work on Trial

Updated Category News Views 68

Thirty-nine devices scattered through a new Hong Kong office may not sound earth-shaking, but this is how workplace technology actually earns its keep: not under trade-show lights, but when somebody is late to a meeting in another time zone and the room has to work anyway. MAXHUB and Canon Hong Kong have launched the first officially delivered Co-Create 100 project...

Continue Reading
A Decade of Giving: Light the World Initiative's Impact

Updated Category News Views 118

The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...

Continue Reading
FULC, DSGR and OPCH Deals Draw Fresh Shareholder Scrutiny

Updated Category News Views 64

Three proposed transactions have drawn the kind of legal glare that makes shareholders sit up and check the fine print twice. On November 18, 2026, Halper Sadeh LLC said it was investigating deals involving Fulcrum Therapeutics, Distribution Solutions Group, and Option Care Health for possible federal securities-law violations or fiduciary-duty breaches. That is not a...

Continue Reading
New Flight Charters Puts a Cap on Winter Surprises

Updated Category News Views 175

Ice on a wing is routine; ice on an invoice is where charter customers start muttering. New Flight Charters says it will again absorb de-icing and hangar charges this winter, up to $2,500 per trip, marking the seventh consecutive season for the program. In a business where the headline quote can look tidy and the final bill can arrive wearing muddy boots, that is a...

Continue Reading
Xailient Tops NIST for Real-World AI Face Recognition

Updated Category News Views 87

In a world where bigger ain't always better, Xailient's latest triumph at NIST's face recognition test has set them apart. On November 17, 2026, the U.S. National Institute of Standards and Technology (NIST) crowned Xailient as the leader in face recognition accuracy for on-device AI, leaving 105 others in the dust. This ain't your run-of-the-mill achievement—it shows...

Continue Reading
MetaComp Targets ASEAN's Cross-Border Payment Snarl

Updated Category News Views 30

ASEAN payment plumbing is still a patchwork, and MetaComp is betting that patchwork has finally become painful enough to fix. The Singapore-based payments firm says its StableX Agentic Network has topped 1,000 members and reaches more than 100,000 users in its first year. That is a respectable early footprint, not a victory lap. Cross-border payments are littered with...

Continue Reading
Cavalry’s I-70 Towing Bet Starts With Columbus Base

Updated Category News Views 71

A jackknifed tractor-trailer does not care about a private-equity playbook. It needs the right rig, a trained crew and somebody arriving before a blocked highway turns into an all-day mess. That unglamorous reality is exactly why Southfield Capital’s new Cavalry Fleet Services platform deserves a closer look. Commercial towing is a necessary, hard-edged local business...

Continue Reading
Mike Blyth’s Hall of Fame Honors a Builder’s Legacy

Updated Category News Views 147

Recognition earned in the hangar, not a boardroom Aircraft design has a ruthless way of exposing empty talk, which is why Mike Blyth’s November 11 induction into the EAA Homebuilders Hall of Fame carries real weight. The Experimental Aircraft Association’s honor, presented in the Eagle Hangar at the EAA Aviation Museum in Oshkosh, Wisconsin, recognizes a career built...

Continue Reading

Top 5 Most Recently Viewed Articles

Taiwan Semiconductor Rises as AI Demand Fuels Growth Potential

Updated Category News Views 226

Taiwan Semiconductor's Recent Performance Taiwan Semiconductor Manufacturing Company Ltd (NYSE: TSM) has witnessed impressive trading activity, nearing its 52-week high recently. The surge in stock price can be attributed to the increasing demand for AI technologies, which continues to invigorate the semiconductor industry. Analyst Insights on TSM Buy Rating and Price...

Continue Reading
TENX Plummets 85%: Shareholder Lawsuits Loom

Updated Category News Views 26

When Clinical Trials Go South When a Phase 3 trial misses its mark, you can bet the market's gonna react, and not in the way anyone holding shares of Tenax Therapeutics (NASDAQ:TENX) wanted. Last week, TENX lost a jaw-dropping 84-85% of its value in just one trading session. The culprit? The Phase 3 LEVEL trial of TNX-103 that failed to deliver—not hitting its primary...

Continue Reading
An Unforgettable Evening: Ismael Cala Foundation's Gala

Updated Category News Views 287

A Night of Elegance with the Ismael Cala Foundation A night of elegance, music, and Cuban culture to promote El Vuelo de la Cometa (The Flight of the Kite) An Enchanting Experience in a Tropical Paradise This year, the Ismael Cala Foundation is set to host its remarkable Legacy of Light Gala at the breathtaking Cala Botanic Sanctuary. Under the serene glow of the Full...

Continue Reading
FDCTech, Inc. Pursues Strategic Acquisition of Xoala in Europe

Updated Category News Views 171

FDCTech, Inc. Sets Course for European Market Expansion FDCTech, Inc. is taking a bold step into the European payments sector with the planned acquisition of Xoala, a regulated electronic money institution. This acquisition could reshape FDCTech's operational landscape, paving the way for growth in a market valued at approximately $2 trillion. Strategic Significance of...

Continue Reading
Heineken N.V. Updates on Its Share Buyback Program's Progress

Updated Category News Views 154

Heineken N.V. Provides Insights on Share Buyback Program Heineken N.V. is currently engaging in a share buyback program that reflects its commitment to enhancing shareholder value. Recently, the company disclosed substantial updates regarding transactions executed under the initial tranche of this program. Heineken N.V. (EURONEXT: HEIA; OTCQX: HEINY) announced that it has...

Continue Reading